Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.

Hao Fu Jinxiong Huang Tianzhi Zhao Hongjian Wang Yuhang Chen Weizhi Xu Yizhen Pang Wei Guo Long Sun Hua Wu Pengfei Xu Bishan Su Jingjing Zhang Xiaoyuan Shawn Chen Haojun Chen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

FAP-targeted radioligand therapy with 177Lu-LNC1004 at 3.33 GBq/cycle was well tolerated in patients with advanced mRAIR-TC, with high radiation dose delivery to the tumor lesions, encouraging therapeutic efficacy, and acceptable side effects.

Keyphrases

endothelial cells
cancer therapy
squamous cell carcinoma
clinical trial
open label
stem cells
mesenchymal stem cells
binding protein